Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ZL-6201

Phase 1Small molecule

ZZai Lab (Shanghai) Co., Ltd.

ZL-6201 is one of 11 small molecule programs targeting Solid Tumors. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

10

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorsRecruiting

Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

13 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Lynparza

Lenvima

Claritin

PPerrigo Company

MK-4280A

MK-4280

Rozlytrek

Asprin

RRoyan Institute

Anti-PD-1 Antibody

Boehringer Ingelheim

Bemarituzumab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Solid Tumors

NCT07374848

Clinical

Trials by Indication[1]

Solid Tumors1 trial

An Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT07374848·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ZL-6201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZL-6201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZL-6201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zai Lab (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZai Lab (Shanghai) Co., Ltd.

Related News